Livzon Pharmaceutical’s 2025 Deals with Livzon MAB Unveiled

Livzon Pharmaceutical Group (HK:1513) has released an update.

Livzon Pharmaceutical Group has approved two significant agreements with Livzon MAB for 2025, involving leasing assets and purchasing drugs, with annual caps set at RMB39 million and RMB54 million respectively. These transactions, classified under connected transactions, are subject to reporting requirements but exempt from shareholder approval under Hong Kong Listing Rules. Key figures in the company with vested interests abstained from board voting to ensure transparency.

For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.